The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).
 
Samuel Aaron Goldlust
Employment - Regional Cancer Care Associates
Leadership - Cellevolve
Stock and Other Ownership Interests - COTA
Honoraria - Cornerstone Specialty Network; Daiichi Sankyo/Astra Zeneca; Physicans' Education Resource
Consulting or Advisory Role - Boston Biomedical; Cellevolve; Cornerstone Specialty Network; Daiichi Sankyo/Astra Zeneca; Novocure; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Novocure
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); AlgoTX (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Candel Therapeutics (Inst); Cantex Pharmaceuticals (Inst); Celgene (Inst); Celldex (Inst); Celularity (Inst); CNS Healthcare (Inst); Cortice Biosciences (Inst); Diffusion Pharmaceuticals (Inst); Epitopoietic Research Corporation (Inst); ImmunoCellular Therapeutics (Inst); Imvax (Inst); Imvax (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Novogen (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tocagen (Inst); Veloxis (Inst); Wex Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Novocure
 
Jong Hee Chang
No Relationships to Disclose
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Novocure; Ono Pharmaceutical; Sumitomo Dainippon Pharma Oncology
Consulting or Advisory Role - Dainippon Sumitomo Pharma
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Stella pharma (Inst); Taiho Pharmaceutical (Inst)
 
Mary Roberta Welch
Research Funding - Boston Biomedical; Inovio Pharmaceuticals
Travel, Accommodations, Expenses - Boston Biomedical; Inovio Pharmaceuticals
 
Richard M. Green
No Relationships to Disclose
 
Jan Drappatz
Leadership - Elsevier
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Pfizer
Honoraria - Elsevier; UpToDate
Consulting or Advisory Role - Agios; Immunomic Therapeutics; Novocure; Oncorus
Patents, Royalties, Other Intellectual Property - uptodate
 
David Eric Piccioni
No Relationships to Disclose
 
Yu Jung Kim
No Relationships to Disclose
 
Jason M. Melear
Consulting or Advisory Role - TG Therapeutics
Speakers' Bureau - AstraZeneca; Janssen
 
Shota Tanaka
Honoraria - Chugai Pharma; Daiichi-Sankyo Co., Ltd.; Eisai; Novocure
Research Funding - Eisai; Ono Pharmaceutical; Sumitomo Dainippon Pharma co., Ltd.; Takeda Science Foundation
Patents, Royalties, Other Intellectual Property - P2019-095102; PCT/JP2020/019814
 
Kuo-Chen Wei
No Relationships to Disclose
 
Karen L. Fink
Research Funding - Agios (Inst); CNS Pharmaceuticals (Inst); Denovo Biopharma (Inst); Incyte (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Orbus Therapeutics (Inst); Translational Genomics Research Institute (Inst)
 
Marshall W. Pitz
No Relationships to Disclose
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; SERVIER; SonaCare Medical; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research
 
John Frederick de Groot
Employment - Alaunos Therapeutics (I); Brii Biosciences (I)
Stock and Other Ownership Interests - Alaunos Therapeutics (I); Brii Biosciences (I); WuXi Biologics
Consulting or Advisory Role - Agios; Aucentra Therapeutics; Bioasis Technologies; CarThera; Chimerix; Cure Brain Cancer Foundation; InSightec; Karyopharm Therapeutics; Kazia Therapeutics; Kintara Therapeutics; Merck; Midatech Pharma; Monteris Medical; Mundipharma Research; Samus Therapeutics; Sapience Therapeutics; Sumitomo Dainippon Pharma Oncology; VBI Vaccines
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - Chimerix; VBI Vaccines
 
Nanci McClellan
Employment - Sumitomo Pharma Oncology
 
Matthew Hitron
Employment - Sumitomo Pharma Oncology
 
Bo Xu
Employment - Sumitomo Pharma Oncology
 
Bo Jin
Employment - Sumitomo Pharma Oncology
 
Claudia Lebedinsky
Employment - Sumitomo Dainnipon Pharma Oncology
Patents, Royalties, Other Intellectual Property - US patent application submitted, title: Methods of treating myeloproliferative neoplasms. Pending patent.